NMRA
Neumora Therapeutics, Inc.
NASDAQ: NMRA · HEALTHCARE · BIOTECHNOLOGY
$2.25
+0.00% today
Updated 2026-04-29
Market cap
$405.57M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.45
Dividend yield
—
52W range
$1 – $4
Volume
1.1M
WallStSmart proprietary scores
24
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$8.91
+296.00%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy5 Buy1 Hold0 Sell1 Strong Sell
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-47.97M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-130.90M | $-235.93M | $-243.79M | $-236.93M | $-59.45M |
| EPS | — | — | — | — | $-1.45 |
| Free cash flow | $-115.41M | $-163.40M | $-182.94M | $-206.44M | $-47.97M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Neumora Therapeutics, Inc. trades at $2.25. Our Smart Value Score of 24/100 indicates the stock is weak.
Frequently asked questions
What is Neumora Therapeutics, Inc.'s stock price?
Neumora Therapeutics, Inc. (NMRA) trades at $2.25.
Is Neumora Therapeutics, Inc. overvalued?
Smart Value Score 24/100 (Grade F, Strong Sell).
What is the price target of Neumora Therapeutics, Inc. (NMRA)?
The analyst target price is $8.91, representing +296.0% upside from the current price of $2.25.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-121.20%
Beta3.12
50D MA$2.68
200D MA$2.17
Shares out0.18B
Float0.10B
Short ratio—
Avg volume1.1M
Performance
1 week-2.60%
1 month+16.58%
3 months+10.29%
YTD+25.70%
1 year—
3 years—
5 years—